Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Urges Investors Suffering Losses Exceeding $50,000 In Applied Therapeutics (NASDAQ: ) To Contact Him Directly To Discuss Their Options

If you suffer losses in excess of $50,000 in Applied Therapeutics January 3, 2024 and December 2, 2024 and want to discuss your legal rights, call a Faruqi & Faruqi partner Direct Josh Wilson on 877-247-4292 or 212-983-9330 (Ext. 1310).

(You can also click here for more information)

New York, New York–(Newsfile Corp. – January 12, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) and reminds investors of February 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the defendants provided positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts about the true status of Applied Therapeutics’ Phase III INSPIRE test; specifically, electronic data acquisition issues and a dosing error in the dose-escalation phase of the study. Such statements without these material facts caused the Plaintiff and other shareholders to buy the securities of Applied Therapeutics at artificially increased prices.

On November 27, 2024, Applied Therapeutics issued a press release announcing “that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for a New Drug Application (NDA) for of goverestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia, ”

On this news, Applied Therapeutics’ stock price fell $1.64 per share, or 16.06%, to close at $8.57 per share on November 27, 2024.

Subsequently, on December 3, 2024, the FDA posted on its website a Warning Letter to Applied Therapeutics, the content of which indicates that the Company was aware even in May 2024 that the FDA had identified significant issues with the goverestat NDA .

On this news, Applied Therapeutics’ stock price fell $0.31 per share, or 18.34%, to close at $1.38 per share on December 4, 2024.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is substantially and generally among the class members managing and managing the litigation on behalf of the purported class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a non-class member. Your ability to share in any recovery is not affected by the decision to serve as lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information about Applied Therapeutics’ conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Follow us for updates on LinkedIn, on X, or on Facebook (NASDAQ:).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar result with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated confidentially.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236773